Clinical Trial Update: A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating WNT974 for metastatic head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• WNT974

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Squamous Cell Carcinoma, Head And Neck | Phase 2 | Status: WITHDRAWN